Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco has partnered with Ducks Unlimited to enhance environmental sustainability in beef cattle production across North America. From 2021 to 2023, Elanco will invest $50,000 annually to purchase grass seed for reseeding projects in western Kansas, aiming to restore 1,000 acres through the SAFE initiative. This collaboration aligns with Elanco’s sustainability framework, Healthy Purpose. Additionally, the announcement coincides with the launch of Experior™, a product approved by the FDA to reduce ammonia emissions from cattle waste, underscoring Elanco's commitment to sustainable agriculture.
Elanco Animal Health (NYSE: ELAN) will announce its first quarter 2021 financial results on May 7, 2021. A conference call will follow at 8:00 a.m. ET, accessible to investors, media, and the public via a webcast on Elanco’s website. This event aims to provide detailed insights into the company's performance during the quarter. Elanco is focused on innovating products to improve animal health, with nearly 70 years of experience in the industry.
Elanco Animal Health (NYSE: ELAN) responded to a U.S. House subcommittee request regarding misleading media claims about Seresto collars. The company reaffirms the safety and efficacy of Seresto, stating no recall is warranted. Over 25 million collars have been sold since 2012 with an adverse event rate below 0.3%, primarily non-serious. Elanco collaborates with the subcommittee and emphasizes the lack of scientific basis for a recall. The company underscores its commitment to product safety and continuous monitoring of health data.
Morris Animal Foundation is collaborating with Elanco Animal Health (NYSE: ELAN) to investigate osteoarthritis (OA) in dogs through data from the Golden Retriever Lifetime Study. This study highlights that approximately 14 million adult dogs in the U.S. suffer from OA, often diagnosed in their senior years. Elanco will enhance questionnaires to evaluate OA signs, including walking gait and joint range of motion. The Golden Retriever Lifetime Study is a significant research initiative involving over 3,000 dogs to assess health factors contributing to diseases, including cancer.
Elanco Animal Health Incorporated (NYSE: ELAN) reported its Q4 and full year 2020 financial results, exceeding guidance due to strong performance in U.S. Pet Health and Farm Animal sectors. Revenue reached $1,140 million, surpassing the $1,040 - $1,070 million guidance. Adjusted EPS met expectations, reflecting ongoing productivity efforts. Elanco is optimistic about 2021, raising guidance based on its Innovation, Portfolio, Productivity strategy and solid fundamentals. The company is focused on capturing synergies from the Bayer Animal Health acquisition, enhancing its market position.
Elanco Animal Health (NYSE: ELAN) announced the departure of executive vice president Michael-Bryant Hicks on March 2. Hicks played a crucial role since 2018 in guiding the company through its IPO and the acquisition of Bayer Animal Health. CEO Jeff Simmons expressed gratitude for Hicks' contributions, emphasizing his unique skill set in transforming Elanco into a standalone entity. Hicks plans to leverage his experience in future leadership roles. The company is currently in the process of finding a replacement for Hicks.
Elanco Animal Health (NYSE: ELAN) has announced significant innovation milestones, including two crucial product approvals. The U.S. FDA approved Increxxa™ for treating bovine and swine respiratory diseases, while Health Canada approved Experior™ 50, the first animal health product aimed at reducing ammonia emissions. In Europe, positive progress was made for Credelio Plus Chewable tablets, and Credelio CAT is expected to receive FDA approval soon. These advancements are expected to drive Elanco's growth, with an anticipated $500-$600 million in new product revenues by 2025.
Elanco Animal Health (NYSE: ELAN) will participate in the Cowen 41st Annual Health Care Conference on March 2, 2021, at 2:50 p.m. ET. Jeff Simmons, the president and CEO, will engage in a virtual fireside chat. A live audio webcast will be available on Elanco's investor website, with replay access for 90 days. Elanco is dedicated to innovating products for the health of animals, following a mission of Food and Companionship Enriching Life.
Elanco Animal Health (NYSE: ELAN) will participate in the BofA Securities Animal Health Virtual Summit on February 25, 2021, featuring a fireside chat with CEO Jeff Simmons at 3:30 p.m. ET. A live audio webcast will be accessible on Elanco’s investor website, with a replay available for 90 days. Elanco is dedicated to innovating animal health products for farm animals and pets, supporting the health of animals, people, and the planet.
Elanco Animal Health (NYSE: ELAN) will release its fourth quarter 2020 financial results on February 24, 2021. A conference call will take place at 8:00 a.m. ET to discuss the results with investors, media, and the public. Participants can access the call via a live webcast on Elanco's website. Established nearly 70 years ago, Elanco is a global leader in animal health, focusing on innovating products and services for farm animals and pets, while promoting sustainability and improving animal health.